Scientists from Spain’s National Cancer Research Center found that suppressing the activity of a specific molecule, TIMP1, increases the effectiveness of immunotherapy and prevents cancer metastasis to the brain. Research results It was published In Cancer Discovery (CD).
Researchers explained that the human body has a strong defense system, that is, the immune system. But cancer often subtly manipulates this system, causing it to expand and spread. Immunotherapy aimed at restoring normal function can sometimes be less effective than expected.
In a new study, scientists looked for methods to increase the effectiveness of immunotherapy. They found that astrocytes, a type of brain cells, can act as immunomodulators. In the presence of metastases (secondary tumors), astrocytes may deviate from their original role, exacerbating tumor growth.
During the experiments, an important element in this process was identified: the TIMP1 molecule. It blocks the activity of the protective cells of the immune system. According to the scientists, this makes TIMP1 a promising biomarker for detecting brain metastases.
Researchers have proposed a new approach to immunotherapy focusing on astrocytes. It combines the use of immunotherapies with drugs that block the production of the TIMP1 molecule.
The study authors noted that a drug called silibinin already exists that successfully inhibits TIMP1 activity. A clinical trial is currently ongoing to evaluate its effectiveness against secondary cancers in the brain.
Previously found A new approach to the treatment of Alzheimer’s disease.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.